Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8566 to 8580 of 8944 results

  1. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]

    In development Reference number: GID-TA10404 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TSID10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    In development Reference number: GID-TA11655 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

    Medical technologies guidance
    Discontinued

  9. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued Reference number: GID-TA10026

    Technology appraisal guidance
    Discontinued

  10. Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

    In development Reference number: GID-TA10774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    In development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]

    In development Reference number: GID-TA11884 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    In development Reference number: GID-TA11008 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]

    In development Reference number: GID-TA11908 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nivolumab + Brentuximab vedotin for Hodgkin lymphoma [ID6691]

    In development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    In development